Fact CheckerSign in

NCT06943625Recruiting

Combined Effects of Green Light and Transcranial Direct Current Stimulation in Migraine Patients.

Combined Effects of Green Light and Transcranial Direct Current Stimulation on Migraine Intensity and Frequency in Migraine Patients.

Source: ClinicalTrials.gov · Last updated 5 Jan 2026

Brief summary (registry, in English)

According to the Global Burden of Disease (GBD) study, headache disorders are among the most prevalent and disabling conditions worldwide, with estimated 1-year prevalence of migraine (22.5%) in Pakistan, considerably higher than the global 1-year prevalence of 15%. The treatment options comprise such as lifestyle modifications, behavioral therapy, medication such as nonsteroidal anti-inflammatory drugs (NSAIDs), beta blockers, calcium channel blockers, antiepileptic drugs or antibodies against calcitonin gene-related peptide (CGRP) or its receptor, and neuromodulation. One of the non-invasive neuromodulation technique is used in migraine patients .i.e., transcranial direct current stimulation (tDCS), tDCS is a promising method for migraine treatment delivering a low-intensity current through the scalp by means of electrodes to modulate the state of polarization of the cerebral cortex; depending on the polarity of the electrical stimulation, tDCS can be either anodal(excitatory) or cathodal(inhibitory). Neuromodulation by tDCS is thought to follow Hebbian Theory ("neurons that fire together, wire together"). If presynaptic and postsynaptic neurons are both active, the result is synaptic strengthening; if one or both are inactive, no change occurs. The literature reported significant reduction in migraine days when applying tDCS to the occipital cortex, primary motor cortex, or the dorsolateral prefrontal cortex. The advantages of tDCS treatment are its relatively low cost compared to other neurostimulator methods, safety and generally mild side effects.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
40 (estimated)
First submitted
17 Apr 2025
Start date
24 Apr 2025
Primary completion date
31 Mar 2026
Lead sponsor
Riphah International University
Diseases
Migraine
NCT number
NCT06943625

What you commit to

  • Study type: Interventional
  • Planned participants: 40
  • From 24 Apr 2025 to the primary completion date, 31 Mar 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Presence of shunt and/or implant at the cranial region

Other illness

  • Mental illness

Other

  • Photophobic individual
  • Brain tumors
  • Wound at skull

Who the study is looking for

  • Episodic migraine or chronic migraine according to the International Headache Society
  • An average headache pain intensity of migraine episodes of ≥5 at numeric pain scale (NPS) over the 4 weeks prior to enrolling in the study

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Pakistan Railway Hospital
Coordinator of this site? Confirm its status
RawalpindiPakistanRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.